GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.

Have any questions? Please email us at ecoliwiki@gmail.com


Jump to: navigation, search


You don't have sufficient rights on this wiki to edit tables. Perhaps you need to log in. Changes you make in the Table editor will not be saved back to the wiki

See Help for Help on this wiki. See the documentation for how to use the table editor


Walter, W, Lingnau, K, Schmitt, E, Loos, M and Maeurer, MJ (2000) MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br. J. Cancer 83:1192-201


Qualitative differences in the MHC class II antigen processing and presentation pathway may be instrumental in shaping the CD4+ T cell response directed against tumour cells. Efficient loading of many MHC class II alleles with peptides requires the assistance of H2-M, a heterodimeric MHC class II-like molecule. In contrast to the HLA-DM region in humans, the beta-chain locus is duplicated in mouse, with the H2-Mb1 (Mb1beta-chain distal to H2-Mb2 (Mb2) and the H2-Ma (Ma) alpha-chain gene). Here, we show that murine MHC class II and H2-M genes are coordinately regulated in murine tumour cell lines by T helper cell 1 (IFN-gamma) and T helper cell 2 (IL-4 or IL-10) cytokines in the presence of the MHC class II-specific transactivator CIITA as determined by mRNA expression and Western blot analysis. Furthermore, Malphabeta1 and Malphabeta2 heterodimers are differentially expressed in murine tumour cell lines of different histology. Both H2-M isoforms promote equally processing and presentation of native protein antigens to H2-A(d)- and H2-E(d)-restricted CD4+ T cells. Murine tumour cell lines could be divided into three groups: constitutive MHC class II and CIITA expression; inducible MHC class II and CIITA expression upon IFN-gamma-treatment; and lack of constitutive and IFN-gamma-inducible MHC class II and CIITA expression. These differences may impact on CD4+ T cell recognition of cancer cells in murine tumour models.


PubMed PMC2363595 Online version:10.1054/bjoc.2000.1415


Animals; Antigen Presentation; Blotting, Western; CD4-Positive T-Lymphocytes/cytology; CD4-Positive T-Lymphocytes/immunology; Dimerization; Gene Expression Regulation, Neoplastic/drug effects; HLA-D Antigens/chemistry; HLA-D Antigens/genetics; HLA-D Antigens/metabolism; Histocompatibility Antigens Class II/genetics; Histocompatibility Antigens Class II/immunology; Interferon-gamma/pharmacology; Interleukin-10/pharmacology; Interleukin-4/pharmacology; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nuclear Proteins; Protein Isoforms/chemistry; Protein Isoforms/genetics; Protein Isoforms/metabolism; RNA, Messenger/drug effects; RNA, Messenger/genetics; RNA, Messenger/metabolism; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Trans-Activators/genetics; Tumor Cells, Cultured/drug effects; Tumor Cells, Cultured/immunology; Tumor Cells, Cultured/metabolism